BR112014026305A2 - derivado de quinazolidinadiona - Google Patents

derivado de quinazolidinadiona

Info

Publication number
BR112014026305A2
BR112014026305A2 BR112014026305A BR112014026305A BR112014026305A2 BR 112014026305 A2 BR112014026305 A2 BR 112014026305A2 BR 112014026305 A BR112014026305 A BR 112014026305A BR 112014026305 A BR112014026305 A BR 112014026305A BR 112014026305 A2 BR112014026305 A2 BR 112014026305A2
Authority
BR
Brazil
Prior art keywords
derivative
quinazolidinedione
formula
pharmaceutically acceptable
relates
Prior art date
Application number
BR112014026305A
Other languages
English (en)
Inventor
Kawada Hatsuo
Shimada Hideaki
Tanaka Hiroshi
Hada Kihito
Niizuma Satoshi
Hara Sousuke
Murata Takeshi
Mio Toshiyuki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112014026305A2 publication Critical patent/BR112014026305A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

abstract the present invention relates to quinazolinedione derivatives represented by formula (i) or pharmaceutically acceptable salts thereof. tradução do resumo resumo patente de invenção: "derivado de quinazolidina-diona". a presente invenção refere-se a um derivado de quinazoli-dinadiona ou um sal farmaceuticamente aceitável do mesmo o qual é representado pela fórmula (i).
BR112014026305A 2012-04-24 2013-04-24 derivado de quinazolidinadiona BR112014026305A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012098954 2012-04-24
PCT/JP2013/062006 WO2013161853A1 (ja) 2012-04-24 2013-04-24 キナゾリンジオン誘導体

Publications (1)

Publication Number Publication Date
BR112014026305A2 true BR112014026305A2 (pt) 2017-06-27

Family

ID=49483161

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026305A BR112014026305A2 (pt) 2012-04-24 2013-04-24 derivado de quinazolidinadiona

Country Status (15)

Country Link
US (1) US9567304B2 (pt)
EP (1) EP2842946B1 (pt)
JP (1) JP6130828B2 (pt)
KR (1) KR20150003849A (pt)
CN (1) CN104379568A (pt)
AR (1) AR090835A1 (pt)
AU (1) AU2013253541A1 (pt)
BR (1) BR112014026305A2 (pt)
CA (1) CA2871453A1 (pt)
HK (1) HK1203943A1 (pt)
MX (1) MX2014012992A (pt)
RU (1) RU2014146993A (pt)
SG (1) SG11201406860SA (pt)
TW (1) TW201348213A (pt)
WO (1) WO2013161853A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150013563A (ko) 2012-04-24 2015-02-05 추가이 세이야쿠 가부시키가이샤 벤즈아미드 유도체
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CA2961033A1 (en) 2014-09-11 2016-03-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
ES2764731T3 (es) 2015-08-31 2020-06-04 Toray Industries Derivado de urea y utilización del mismo
US10519106B2 (en) 2015-08-31 2019-12-31 Toray Industries, Inc. Urea derivative and use therefor
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20230060425A1 (en) 2019-02-26 2023-03-02 Bayer Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
CN110218193A (zh) * 2019-07-08 2019-09-10 山东大学 3-羟基喹唑啉-2,4(1h,3h)-二酮类衍生物及其制备方法与应用
CN112608282B (zh) * 2019-12-20 2022-07-26 山东先达农化股份有限公司 一种含喹唑啉二酮和n-o结构的化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK570987A (da) 1986-12-01 1988-06-02 Hoffmann La Roche Oxadiazol-, thiadiazol- og triazolforbindelser
JP2751309B2 (ja) 1988-02-16 1998-05-18 三菱化学株式会社 ピラゾール類およびこれを有効成分とする殺虫、殺ダニ、殺菌剤
JPH05255268A (ja) 1992-03-17 1993-10-05 Mitsubishi Kasei Corp ピラゾールカルボキサミド類、これを有効成分とする殺虫、殺ダニ剤および農園芸用殺菌剤
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3488890B2 (ja) 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
AU2002352444A1 (en) * 2001-12-20 2003-07-09 Celltech R And D Limited Quinazolinedione derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
MXPA06007237A (es) 2003-12-25 2006-08-18 Nippon Shinyaku Co Ltd Derivado de amida y medicamento que lo contiene.
US7511062B2 (en) 2004-05-18 2009-03-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
EP1806337A4 (en) 2004-10-08 2009-11-25 Banyu Pharma Co Ltd METHOD FOR THE SYNTHESIS OF A THIOETHER COMPOUND
JP2009528992A (ja) 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
FR2921926B1 (fr) 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
WO2009080638A2 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
AU2009226153B2 (en) 2008-03-19 2014-02-20 Chembridge Corporation Novel tyrosine kinase inhibitors
PE20091784A1 (es) 2008-04-23 2009-12-05 Takeda Pharmaceutical Derivados de iminopiridina con actividad sobre el receptor adrenergico alfa 1d
TW201006823A (en) 2008-07-14 2010-02-16 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
JP2012505881A (ja) 2008-10-15 2012-03-08 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
AU2010310705A1 (en) * 2009-10-23 2012-04-19 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JO3634B1 (ar) * 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
JP5781636B2 (ja) 2011-03-14 2015-09-24 インパクト セラピューティックス インコーポレイテッド キナゾリンジオン及びその使用
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
CN104066723B (zh) 2011-11-01 2016-06-29 南京英派药业有限公司 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用
KR20150013563A (ko) 2012-04-24 2015-02-05 추가이 세이야쿠 가부시키가이샤 벤즈아미드 유도체

Also Published As

Publication number Publication date
US9567304B2 (en) 2017-02-14
WO2013161853A1 (ja) 2013-10-31
EP2842946A4 (en) 2015-09-09
CA2871453A1 (en) 2013-10-31
JPWO2013161853A1 (ja) 2015-12-24
SG11201406860SA (en) 2014-11-27
RU2014146993A (ru) 2016-06-10
EP2842946B1 (en) 2016-09-28
TW201348213A (zh) 2013-12-01
JP6130828B2 (ja) 2017-05-17
KR20150003849A (ko) 2015-01-09
MX2014012992A (es) 2015-08-14
EP2842946A1 (en) 2015-03-04
AR090835A1 (es) 2014-12-10
CN104379568A (zh) 2015-02-25
AU2013253541A1 (en) 2014-11-20
US20150141400A1 (en) 2015-05-21
HK1203943A1 (en) 2015-11-06

Similar Documents

Publication Publication Date Title
BR112014026305A2 (pt) derivado de quinazolidinadiona
BR112014026266A2 (pt) derivado de quinazolidinadiona
BR112015018738A2 (pt) compostos de tetra-hidropirrolotiazina
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015000399A2 (pt) derivados de pirazolil pirimidina
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
BR112015026967A2 (pt) compostos fenoxietil di-hidro-1h-isoquinolina
ECSP12012290A (es) Formulaciones farmacéuticas
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112015021240A2 (pt) processo para sal de sódio de (2s, 5r)-2-carboxamido-7-oxo-6-sulfo-oxi-1,6-diaza-biciclo[3.2.1]octano
CR20130419A (es) Derivados heterocíclicos de amina
BR112015019276A2 (pt) compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112016029825A2 (pt) composto
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
BR112015029348A2 (pt) inibidores da bace
BR112014031616A2 (pt) compostos de fenoxietil piperidina
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012031340A2 (pt) derivados de cianoquinolina
BR112014026198A2 (pt) compostos pirazol como inibidores de sglt1
AR095097A1 (es) Compuestos de fenoxietoxi

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed